

Liste des publications

2018 :

<p>ACCORD 03</p>	<p>Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03).</p>	<p>Faivre JC, Peiffert D, Vendrely V, Lemanski C, Hannoun-Levi JM, Mirabel X, Stanbury T, Salleron J, Guillemin F.</p>	<p>Radiother Oncol. 2018 Aug 29. doi: 10.1016/j.radonc.2018.08.008</p>	<p>https://www.ncbi.nlm.nih.gov/pubmed/30172453</p>
<p>UCGI 29 Prodige 52</p>	<p>Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial.</p>	<p>Bennouna J, André T, Campion L, Huret S, Miglianico L, Mineur L, Toucheffeu Y, Artru P, Asmis T, Bouché O, Borde F, Kavan P, Lam YH, Rajpar LS, Emile JF, Jouffroy C, Gill S, Taïeb J.</p>	<p>Clin Colorectal Cancer. 2018 Oct 19. doi: 10.1016/j.clcc.2018.09.011.</p>	<p>https://www.ncbi.nlm.nih.gov/pubmed/30415988</p>
<p>ACCORD 24- PRODIGE 24</p>	<p>FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.</p>	<p>Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB</p>	<p>N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMOA1809775.</p>	<p>https://www.ncbi.nlm.nih.gov/pubmed/30575490</p>

2017 :

ACCORD 17- PRODIGE 5	Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracilecisplatin regimen in oesophageal cancer.	Bascoul-Mollevi C, Gourgou S, Galais MP, Raoul JL, Bouché O, Douillard JY, Adenis A, Etienne PL, Juzyna B, Bedenne L, Conroy T	Eur J Cancer. 2017 Oct;84:239-249	https://www.ncbi.nlm.nih.gov/pubmed/?term=Health-related+quality+of+life+results+from+the+PRODIGE+5%2FACCORD+17+randomised+trial+of+FOLFOX+versus+fluorouracilecisplatin+regimen+in+oesophageal+cancer
PRODIGE 17- ACCORD 20	Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.	Pernot S, Badoual C, Terme M, Castan F, Cazes A, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Bachet JB, Borg C, Ducreux M, Marcheteau E, Stanbury T, Gourgou S, Malka D, Taieb J.	Eur J Cancer. 2017 Jul;79:15-22. doi: 10.1016/j.ejca.2017.03.036. Epub 2017 Apr 26.	https://www.ncbi.nlm.nih.gov/pubmed/28456090
ACCORD 11- PRODIGE 4	Retrospective analysis of CA19-9 decrease in patients with metastatic pancreatic carcinoma treated with FOLFIRINOX or Gemcitabine in a randomized phase III study (ACCORD11/PRODIGE 4).	Marie Robert, Marta Jarlier, Sophie Gourgou , Françoise Desseigne, Marc Ychou, Olivier Bouché, Beata Juzyna, Thierry Conroy, J. Bennouna.	Oncology 2017;93:367-376 doi:10.1159/000477850	https://www.ncbi.nlm.nih.gov/pubmed/28982109
ACCORD 12- PRODIGE 2	Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer.	Azria D, Doyen J, Jarlier M, Martel-Lafay I, Hennequin C, Etienne P, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah J, Mahé M, Bécouarn Y, Dupuis O, Lledo G, Seitz J, Bedenne 1, Gourgou-Bourgade S, Juzyna B, Conroy T, Gérard J.	Ann Oncol. 2017 Oct 1;28(10):2436-2442. doi: 10.1093	https://www.ncbi.nlm.nih.gov/pubmed/28961836?dopt=Abstract